Skip to main content

Advertisement

Table 3 Association between prognostic value of PRDXs mRNA expression and various chemotherapies in BrCa

From: Comprehensive analysis of peroxiredoxins expression profiles and prognostic values in breast cancer

Chemotherapies Cases HR 95% CI P value Cases HR 95% CI P value
OS RFS
PRDX1
 Adjuvant chemotherapy 163 1.85 1.01–3.40 0.044 594 1.05 0.78–1.42 0.734
 Neoadjuvant chemotherapy 156 0.74 0.34–1.60 0.448 223 1.19 0.69–2.03 0.539
 Non-chemotherapy 549 1.13 0.79–1.60 0.502 1873 1.22 1.03–1.44 0.019
PRDX2
 Adjuvant chemotherapy 163 2.02 1.09–3.73 0.023 594 1.33 0.98–1.80 0.064
 Neoadjuvant chemotherapy 156 1.41 0.66–3.02 0.375 223 1.24 0.72–2.16 0.438
 Non-chemotherapy 549 1.14 0.80–1.62 0.483 1873 1.07 0.90–1.26 0.444
PRDX3
 Adjuvant chemotherapy 163 2.03 1.10–3.73 0.021 594 0.80 0.59–1.08 0.148
 Neoadjuvant chemotherapy 156 1.05 0.49–2.23 0.906 223 0.95 0.55–1.65 0.851
 Non-chemotherapy 549 0.79 0.56–1.12 0.185 1873 0.84 0.71–1.00 0.043
PRDX4
 Adjuvant chemotherapy 163 1.97 1.07–3.65 0.027 594 1.02 0.75–1.38 0.906
 Neoadjuvant chemotherapy 156 0.68 0.31–1.48 0.325 223 1.19 0.69–2.07 0.529
 Non-chemotherapy 549 1.28 0.90–1.82 0.177 1873 1.37 1.16–1.62 < 0.001
PRDX5
 Adjuvant chemotherapy 0 1.09 0.58–2.06 0.790 255 0.50 0.30–0.81 0.005
 Neoadjuvant chemotherapy 107 0.67 0.24–1.89 0.446 111 1.22 0.58–2.57 0.595
 Non-chemotherapy 0 0.58 0.29–1.15 0.117 243 0.66 0.38–1.14 0.131
PRDX6
 Adjuvant chemotherapy 163 0.86 0.48–1.56 0.625 594 1.10 0.81–1.49 0.532
 Neoadjuvant chemotherapy 156 0.72 0.33–1.55 0.395 223 1.09 0.63–1.88 0.769
 Non-chemotherapy 549 1.33 0.94–1.88 0.110 1873 1.19 1.00–1.40 0.044